Last reviewed · How we verify

Gastric Hypersecretory Conditions — Treatment Landscape & Competitive Intelligence

Gastric Hypersecretory Conditions (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Gastric Hypersecretory Conditions, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Protonix pantoprazole Generic (originally Byk Gulden/Altana/Nycomed) Proton pump inhibitor (PPI) ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1 2000-02-02
Pantoprazole Sodium Pantoprazole Sodium Pfizer Proton pump inhibitor (PPI) (H+, K+)-ATPase enzyme 2000-01-01
Prevacid lansoprazole Generic (originally Takeda) Proton pump inhibitor (PPI) ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase 1995-05-10
Renacidin MAGNESIUM CARBONATE United Guardian Vitamin C [EPC] 1990-01-01
Prilosec omeprazole AstraZeneca (originally Astra AB) Proton pump inhibitor (PPI) ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19 1989-09-14
Zantac ranitidine GSK (originally Glaxo) H2 receptor antagonist Multidrug and toxin extrusion protein 1, Acetylcholinesterase, Histamine H2 receptor 1983-06-01
Gaviscon MAGNESIUM SILICATE Sanofi magnesium silicate 1983-01-01
Gaviscon ALGELDRATE Sanofi algeldrate 1983-01-01
Bss SODIUM CITRATE B Braun sodium citrate Calcium 1980-01-01
Milk of Magnesia magnesium hydroxide Generic (multiple manufacturers) Osmotic laxative, Antacid Gastric acid (direct neutralization) + osmotic effect in intestine 1880-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 3 drugs in Gastric Hypersecretory Conditions
  2. Sanofi · 2 drugs in Gastric Hypersecretory Conditions
  3. B Braun · 1 drug in Gastric Hypersecretory Conditions
  4. GSK (originally Glaxo) · 1 drug in Gastric Hypersecretory Conditions
  5. Generic (multiple manufacturers) · 1 drug in Gastric Hypersecretory Conditions
  6. Generic (originally Byk Gulden/Altana/Nycomed) · 1 drug in Gastric Hypersecretory Conditions
  7. Generic (originally Takeda) · 1 drug in Gastric Hypersecretory Conditions
  8. Northern Orthopaedic Division, Denmark · 1 drug in Gastric Hypersecretory Conditions
  9. Novartis Pharmaceuticals · 1 drug in Gastric Hypersecretory Conditions
  10. Pfizer · 1 drug in Gastric Hypersecretory Conditions
  11. RenJi Hospital · 1 drug in Gastric Hypersecretory Conditions
  12. United Guardian · 1 drug in Gastric Hypersecretory Conditions

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Gastric Hypersecretory Conditions:

Cite this brief

Drug Landscape (2026). Gastric Hypersecretory Conditions — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/gastric-hypersecretory-conditions. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing